Navigation Links
HeartWare International Announces Appointment Of Katrin Leadley, M.D., As Chief Medical Officer
Date:8/4/2014

as provided excellent stewardship during the past six years," said Godshall.  "Dave has played an integral role in leading us through the clinical process to obtain regulatory approval of the HeartWare® Ventricular Assist System in Europe and as a bridge-to-transplantation therapy in the U.S.  HeartWare values Dave's numerous, meaningful contributions and wishes him well in his retirement, as our organization continues to grow and build upon the foundation he helped us create."

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 40 countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market.

HEARTWARE, HVAD, MVAD, PAL, SYNERGY, CIRCULITE and HeartWare logos are registered trademarks of HeartWare, Inc.

Forward-Looking Statements

This announcement contains forward-looking statements that are based on ma
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013
2. HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues
3. HeartWare Presentation At The Oppenheimer 24th Annual Healthcare Conference To Be Webcast
4. HeartWare Presentation At The 25th Annual Piper Jaffray Healthcare Conference To Be Webcast
5. HeartWare Presentation At The Canaccord Genuity Medical Technology & Diagnostics Forum To Be Webcast
6. HeartWare International Reports $54.8 Million In Third Quarter 2013 Revenue; 140% Increase From Third Quarter Of 2012
7. HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
8. HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference To Be Webcast
9. HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial
10. HeartWare Presentation at the Wells Fargo Securities 2013 Healthcare Conference to be Webcast
11. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Pulmonary Fibrosis Foundation (PFF) and Veracyte, ... the organizations are partnering on a U.S. patient ... with interstitial lung diseases (ILDs), including idiopathic pulmonary ... (INTENSITY) survey will assess the steps and time ...
(Date:8/27/2015)... 27, 2015  QB3@953—a San Francisco ... of California (UC) research institute and biotech accelerator— ... to identify and facilitate collaborations to translate early ... The agreement formalizes a relationship between ... team and creates a new channel for DPAc ...
(Date:8/27/2015)... , Spain and CAMBRIDGE, Mass. , Aug. 27, ... presenting at the Rodman & Renshaw 17th Annual Global Investment ... at the St. Regis Hotel, ORYZON will be represented by ... Dr. Buesa will present this ... at the Fontainebleau Room (2nd Floor).  The company is completing ...
Breaking Medicine Technology:Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4
... EAST SETAUKET, N.Y., Dec. 19, 2011  An article in the ... of the National Academy of Sciences USA , reported ... therapeutic potential in a laboratory model of Gaucher disease  ... and president of Lixte said, "This is a novel ...
... MISSISSAUGA, Ontario, Dec. 19, 2011  Valeant Pharmaceuticals International, ... VRX) announced that effective December 16, 2011, the ... a dermatology unit of Sanofi (EURONEXT: SAN and ... International, Inc. Valeant Pharmaceuticals International, ...
Cached Medicine Technology:Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 2Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 3
(Date:8/27/2015)... ... August 27, 2015 , ... ... with Julia Glushko, professional Tennis player for Israel in the Women’s Tennis Association ... for all her training and recovery. , With a focus on technology and ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor of ... third doctoral program at its main campus in Reading: Doctor of Nursing Practice. , ... to prepare advanced practice nurses for the highest level of clinical nursing practice. ...
(Date:8/27/2015)... GREENWICH, CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract ... agreement to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... partnership agreement for quality market research promotion on the Internet. MarketPublishers.com is ... Analysis. , Commenting on the partnership agreement, Natalie Aster, Assistant Manager at ...
(Date:8/27/2015)... TX (PRWEB) , ... August 27, 2015 , ... ... cutting edge procedure to relieve vaginal discomfort due to pre- and post-menopause, chemotherapy, and ... using a CO2 laser, which delivers controlled energy to the vaginal tissue, revitalizing cells ...
Breaking Medicine News(10 mins):Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3
... Sept. 8 , , WHAT: ... growing radio shows-- The CEO Show-- draws a clever analogy ... upcoming Webinar taken from his book titled, Golf and the Art ... the research and educational arm of Beryl, the nation,s leading healthcare-exclusive call ...
... , , , ... Health Integrated, a leading provider of Health Management Solutions, has ... the health plan integrates the management of behavioral health benefits ... solution, Health Integrated will provide Blue Cross of Idaho with ...
... , Nurses to March for Employee ... in Single-Payer Systems , , SAN ... the largest union and professional association of nurses in U.S. history, ... the biennial convention of California,s largest RN organization, the California Nurses ...
... , , LOS ANGELES, Sept. 8 ... obesity epidemic and a general lack of healthy living. In his new ... Help of a Personal Trainer" ( published by AuthorHouse ), ... lost over 60 pounds with the help of a personal trainer, and ...
... , LONDON, Sept. 8 The 2009 Frost ... Risk Management Award is presented to Pronova BioPharma ASA. The ... FDA-approved omega-3 derived prescription drug. Branded Omacor in Europe ... a prescribed adjunct to diet for the treatment of elevated ...
... , WASHINGTON, Sept. 8 /PRNewswire-USNewswire/ ... health care reform, a new analysis by the Center for ... receive benefits under the House health reform bill (H.R. 3200). ... for the new taxpayer-funded affordability credits, there is nothing in ...
Cached Medicine News:Health News:The Beryl Institute Sponsors Free Customer Service Webinar with Robert Reiss 2Health News:Health Integrated Enters into Agreement with Blue Cross of Idaho to 'Carve-in' Behavioral Health Management 2Health News:1,200 RNs Gather in San Francisco Tuesday: Take Next Step to Form Nation's Largest Ever Union of Nurses 2Health News:The Simple ABCs of Weight Loss and Fitness 2Health News:The Simple ABCs of Weight Loss and Fitness 3Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 2Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 3Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 4Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 5Health News:Health Bill Could Benefit 6.6 Million Illegals 2Health News:Health Bill Could Benefit 6.6 Million Illegals 3
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
4 mm blade. Flat handle....
9 mm button end blade. 15 mm long backcutting blade. Angled at 45 degrees. Flat handle. Designated most popular model or size....
10 mm blade, angled left. Flat handle....
Medicine Products: